What It Is
Selank is a synthetic heptapeptide — a chain of seven amino acids — built from the sequence of tuftsin, a naturally occurring immune-signaling tetrapeptide, with an added Pro-Gly-Pro extension.[1] It was developed in Russia and is studied mainly as a nootropic and anxiolytic compound, proposed to reduce anxiety and support cognitive function, though the evidence behind those labels is uneven.
Selank has a prescription history in Russia, where it has been studied and used clinically for anxiety-related conditions, but it has no equivalent regulatory standing in the United States.[2] That regional gap is one of the most important things to understand about how Selank is discussed online versus how it is actually regulated.
How It Works
Selank's proposed mechanism is not a single confirmed receptor pathway but several overlapping ones. Preclinical research has linked it to changes in GABAergic gene expression, serotonin metabolism, dopamine-related signaling, and the activity of enkephalin-degrading enzymes.[3] In one rat gene-expression study, intranasal Selank altered expression of dozens of genes involved in GABA signaling within hours of administration, which the researchers interpreted as consistent with a possible allosteric effect on GABA-A receptor activity — the same broad system benzodiazepines act on.[3]
These are mechanistic hypotheses generated largely in animal and cell models. They help explain why Selank is biologically plausible as an anxiolytic, but a plausible pathway is not the same as a demonstrated clinical effect.
What the Research Shows
Human evidence for Selank is small, early, and concentrated in Russian clinical literature. A 2008 study compared Selank against the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting broadly similar anxiolytic effects between the two.[4] A 2014 study compared Selank with another benzodiazepine, phenazepam, in 60 patients with phobic-anxiety and somatoform disorders, again reporting anxiolytic benefit alongside mild nootropic effects.[5]
These studies are clinically interesting but limited by small sample sizes, regional publication context, and comparator drugs not standard in U.S. practice. Cognitive, neuroprotective, and stress-resilience claims rest on an even thinner base — mostly rodent studies of memory and chronic-stress models — and should be read as preliminary rather than established.[6]
Safety & Side Effects
Because Selank has no FDA-approved label, there is no standardized adverse-reaction table drawn from large regulated trials. The small human studies available reported general tolerability, but the FDA has separately flagged Selank acetate as a nominated bulk compounding substance associated with potential safety risks — citing possible immunogenicity, aggregation, and peptide-related impurities, along with a lack of adequate human safety information for the routes being proposed.[7]
Interaction data are similarly thin: preclinical work has examined Selank alongside diazepam and olanzapine, raising interaction questions without establishing safe combination use in humans. Pregnancy, breastfeeding, and long-term safety in any population remain largely uncharacterized.
Regulatory Status: Russia vs. FDA
Selank is not FDA-approved. No Selank prescribing label appears in FDA approval databases such as the Orange Book, and the compound instead surfaces in FDA's compounding-risk materials as a substance with unresolved safety questions.[7][8]
This differs from its status in Russia, where Selank has a history as a studied and clinically used peptide preparation for anxiety-related conditions.[4] Approval and clinical use in one country does not transfer to another: readers outside Russia should not treat Russian clinical availability as equivalent to FDA review, and products sold in the U.S. as "Selank" are unregulated research chemicals rather than approved medicines.